TY  - JOUR
TI  - Recombinant AhpC antigen from Mycobacterium bovis boosts BCG-primed
immunity in mice
AB  - Tuberculosis (TB) is still one of the most common infectious diseases around the world despite the widespread use of BCG
(bacille Calmette-Guerin) strain of Mycobacterium bovis as a vaccine. This vaccine does not always protect people from TB, and, thus,
new effective vaccines or vaccination strategies are being investigated. In this study, alkyl hydroperoxide reductase (AhpC) from M.
bovis was evaluated as a new candidate vaccine antigen against TB in BALB/c mice model. The ahpC gene was amplified from M.bovis
genome, cloned, and expressed in Escherichia coli. Vaccine antigen AhpC was formulated with Montanide ISA 61 VG, an oil-based
emulsion adjuvant. Both IgG and IL-12 responses were observed in mice after administering the formulation both as a subunit vaccine
alone and also as a booster vaccine for BCG immunization. However, a long-lasting response was observed when AhpC formulation
was used as a booster (for BCG-primed immunization) as compared to being used as a subunit vaccine alone. In short, these findings
suggested that AhpC has the potential to be used as a booster vaccine candidate for BCG-primed immunization.
AU  - Kazkayasi, Inci
AU  - Duzenli, Ozgun Firat
AU  - OKAY, Sezer
AU  - Oner, Ayse Filiz
DO  - 10.3906/biy-2108-41
PY  - 2022
JO  - Turkish Journal of Biology
VL  - 46
IS  - 1
SN  - 1300-0152
SP  - 95
EP  - 104
DB  - TRDizin
UR  - http://search/yayin/detay/521626
ER  -